First Patient Dosed in DENALI-1 Ph 1/2 Clinical Study of A2B395 CAR T Cell Therapy for Patients with EGFR-expressing Solid Tumors July 1, 2025
CDR609 Announced as New T-Cell Engager Clinical Candidate Targeting LGR5 in Solid Tumors July 1, 2025
Results from Ph 1 FRAME Study of Avutometinib + Defactinib combo in Solid Tumors, including Low-Grade Serious Ovarian Cancer, published in Nature Medicine July 1, 2025
Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion/Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients Filed July 1, 2025
Orion and Glykos announce the extension of research collaboration and licensing agreement for the development of next-gen ADCs June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel ADC Targeting CDH6 June 24, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel CDH6-targeting ADC June 17, 2025
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology June 17, 2025
Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies June 17, 2025
Results from Ph 1/2 Study of Sacituzumab Tirumotecan (sac-TMT) in Solid Tumors Refractory to Standard Therapies Published in Journal of Hematology & Oncology June 17, 2025
Vividion Therapeutics and Bayer Partnership Aims to Further Strengthen Oncology Pipeline With Solid Tumor Inhibitor June 11, 2025
First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
European Commission Approves SC Formulation of Opdivo Across Multiple Solid Tumor Indications June 3, 2025
BioNTech and BMS to Co-Develop and Co-Commercialize BNT327 for Multiple Solid Tumor Types June 3, 2025
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies June 3, 2025
Lumanity and Parker Institute for Cancer Immunotherapy (PICI) Announce Partnership to Accelerate Immunotherapy Innovation June 3, 2025
